Asensus Surgical (NYSE American: ASXC) announced today that FDA has cleared next-gen augmented intelligence capabilities on its Senhance system’s Intelligent Surgical Unit.
The ISU already enabled machine vision-driven camera control; the system responded to the surgeon’s commands and even recognized certain objects and locations in the surgical field. The new ISU features expand the capabilities and introduce more advanced features, including 3D measurement, digital tagging, image enhancement and enhanced camera control — a first for soft-tissue abdominal surgery, according to the company.
“The addition of these pioneering digital capabilities on our existing surgical platform provides real-time intraoperative digital tools to surgeons and underscores our commitment to delivering our vision for performance-guided surgery,” Asensus Surgical CEO Anthony Fernando said in a news release. “This is the latest example of our progress toward delivering on our surgical assurance framework by unlocking the clinical intelligence necessary to enable consistently superior outcomes and a new standard of surgery.”